FDA Approves Medinol’s Drug-Eluting Coronary Stent System
The EluNIR-PERL drug-eluting stent is used for the treatment of coronary artery disease.
Medinol announced that its EluNIR-PERL drug-eluting stent (DES) received approval from FDA. The device is used in the treatment of coronary heart disease.
The design of the stent allows for more precise navigation and placement in complex anatomies.
In a press release, Medinol CEO Yoram Richter said, “We are pleased to bring technologies to the U.S. that focus both on benefit to patients as well as unique and meaningful advantages to surgeons, allowing for precise stent placement, shorter procedure times and reduced radiation exposure.”
In the same press release, CoSo Health CEO Jae Lee stated that CoSo would distribute the device.
"We are proud to distribute one of the world's best drug-eluting stents via our intuitive and easy-to-use SaaS+ platform, which reduces layers in the supply chain," Lee said.
SOURCE
(Oct 24 2023); CoSo Health; Medinol Receives FDA Approval for Next Generation EluNIR-PERL Drug-Eluting Coronary Stent System; https://www.prnewswire.com/news-releases/medinol-receives-fda-approval-for-next-generation-elunir-perl-drug-eluting-coronary-stent-system-301965041.html
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
